Hermetica Superfood Encyclopedia
The Short Answer
Iron Niferex delivers elemental iron via two highly bioavailable matrices — polysaccharide-iron complex (PIC) and ferrous asparto glycinate — which protect iron from gastric degradation, reduce free-radical oxidative stress in the GI tract, and facilitate uptake through the DMT1 transporter after vitamin C-mediated reduction of Fe³⁺ to Fe²⁺. Clinical use is supported for the treatment and prevention of iron deficiency anemia, with the chelated and polysaccharide-bound forms demonstrating superior GI tolerability compared to standard ferrous sulfate at equivalent elemental iron doses in comparative tolerability studies.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary KeywordIron Niferex supplement
Iron Niferex — botanical close-up
Health Benefits
**Iron Deficiency Anemia Treatment**
Elemental iron from PIC and ferrous asparto glycinate is incorporated into hemoglobin via heme synthesis, restoring red blood cell oxygen-carrying capacity in iron-depleted individuals; the once-daily 150 mg elemental iron dose is intended to rapidly replete serum ferritin and hemoglobin levels.
**Improved GI Tolerability vs
Ferrous Salts**: The polysaccharide matrix and chelate structure sequester reactive Fe²⁺/Fe³⁺ ions, reducing direct mucosal oxidative damage and minimizing nausea, constipation, and epigastric pain commonly associated with ferrous sulfate.
**Enhanced Iron Absorption via Vitamin C Co-formulation**
Ascorbic acid (60–175 mg per tablet) chemically reduces Fe³⁺ to the more soluble Fe²⁺ form in the duodenum, increasing uptake efficiency through apical DMT1 transporters on enterocytes and counteracting inhibitory dietary ligands such as phytates and polyphenols.
**Folate-Supported Red Blood Cell Maturation**
Co-formulated Quatrefolic® (5-methyltetrahydrofolate) and folic acid (totaling 1 mg, 1700 mcg DFE) support thymidylate synthesis and DNA methylation required for normal erythropoiesis, addressing concurrent folate deficiency that frequently accompanies iron deficiency anemia.
**Vitamin B12-Facilitated Erythropoiesis**
Cyanocobalamin (25 mcg per tablet) supports methylmalonyl-CoA mutase and methionine synthase activity necessary for megaloblastic anemia prevention; inclusion of desiccated stomach substance/intrinsic factor in select formulations supports ileal B12 absorption in patients with impaired gastric secretion.
**Zinc Repletion During Anemia Treatment**
Zinc bisglycinate chelate (15 mg, 100% DV) provides a bioavailable zinc source that supports immune function, carbonic anhydrase activity, and DNA synthesis without competitively displacing iron absorption at typical therapeutic doses.
**Succinic Acid-Mediated Systemic Iron Transfer**
Succinic acid (50–150 mg) is theorized to support basolateral iron transfer from enterocytes into the portal circulation by modulating mitochondrial energy metabolism and facilitating ferroportin-mediated export, potentially accelerating net iron flux into systemic stores.
Origin & History
Natural habitat
Niferex is a modern pharmaceutical-grade iron supplement developed in the United States, with no geographic or botanical origin. The polysaccharide-iron complex (PIC) component is synthesized by complexing ferric iron (Fe³⁺) with low-molecular-weight polysaccharide chains derived from starch hydrolysates, while ferrous asparto glycinate (marketed as Sumalate®) is produced by chelating ferrous iron with the amino acid aspartate and glycine. Both forms are manufactured in controlled pharmaceutical settings under Good Manufacturing Practice (GMP) standards and are formulated into coated oral tablets or capsules.
“Iron Niferex has no traditional or ethnobotanical history, as it is an entirely synthetic pharmaceutical compound first developed and commercialized in the modern era of clinical nutrition and hematology. The Niferex brand name has been associated with polysaccharide-iron complex formulations in North American pharmacy markets since at least the late twentieth century, initially positioned as a gentler alternative to ferrous sulfate for patients with chronic iron deficiency requiring long-term supplementation. The reformulation of Niferex to incorporate ferrous asparto glycinate (Sumalate®) alongside PIC reflects an industry trend toward multi-matrix iron delivery systems designed to optimize both GI tolerability and net bioavailability using amino acid chelation technology. There are no notable historical medical texts, Ayurvedic references, or traditional herbal systems that describe this compound, as all preparation methods are proprietary pharmaceutical manufacturing processes rather than culinary or ethnomedicinal traditions.”Traditional Medicine
Scientific Research
Niferex-specific randomized controlled trial data with reported hemoglobin effect sizes and patient population numbers are not robustly available in the peer-reviewed literature as of 2024; the product's efficacy claims are extrapolated from the broader body of evidence for polysaccharide-iron complex and amino acid-chelated iron formulations rather than from branded Niferex RCTs. General PIC studies and comparative tolerability investigations suggest that non-ionic iron complexes produce fewer GI adverse events than ferrous sulfate in populations with iron deficiency anemia, though head-to-head superiority in hemoglobin restoration rates has not been definitively established in large multicenter trials. Quality assessments of PIC capsule formulations (e.g., dissolution, content uniformity) have been conducted in pharmaceutical sciences literature, but these address product quality rather than clinical efficacy endpoints such as hemoglobin rise per gram of elemental iron delivered. Clinicians should treat the clinical evidence base for Niferex specifically as limited, relying primarily on extrapolated class evidence for iron supplementation and the mechanistic rationale for improved tolerability with chelated/polysaccharide-bound forms.
Preparation & Dosage
Traditional preparation
**Standard Adult Dose**
150 mg elemental iron (as 50 mg ferrous asparto glycinate + 100 mg PIC in some formulations, or 75 mg ferrous asparto glycinate in others)
1 coated tablet once daily, providing .
**Oral Tablet Form**
Oval, copper-colored film-coated tablets (some embossed '344'); gluten-free, lactose-free, and sugar-free formulations available.
**Capsule Form**
PIC-only capsule versions (46% iron powder by weight) are also available for patients intolerant of tablet excipients.
**Timing**
Best absorbed on an empty stomach or with a small amount of food if GI upset occurs; avoid concurrent intake with antacids, dairy products, tea, or coffee within 2 hours of dosing.
**Standardization**
PIC is standardized to approximately 46% elemental iron by weight; ferrous asparto glycinate (Sumalate®) is standardized to defined elemental iron content per chelated mass.
**Pediatric and Prenatal Use**
Specific pediatric dosing is not established for Niferex-branded products in available references; prenatal use should be directed by a licensed healthcare provider given the high elemental iron load.
**Duration of Therapy**
Iron deficiency anemia typically requires 3–6 months of continuous supplementation to replete body stores after hemoglobin normalization; duration should be guided by serial ferritin monitoring.
Nutritional Profile
Each Niferex tablet provides a concentrated micronutrient payload centered on 150 mg elemental iron as the primary therapeutic component, delivered via polysaccharide-iron complex and/or ferrous asparto glycinate matrices with measurably higher relative bioavailability than ferrous sulfate due to reduced luminal precipitation and alternative transport pathways. Vitamin C (60–175 mg) functions both as a reducing agent enhancing Fe³⁺ to Fe²⁺ conversion and as an antioxidant protecting the GI epithelium from iron-mediated oxidative stress. Folate is present as a combination of Quatrefolic® (6S-5-methyltetrahydrofolate glucosamine salt) for direct cellular utilization independent of MTHFR polymorphism status and folic acid, totaling 1 mg (1700 mcg DFE). Cyanocobalamin contributes 25 mcg B12 (417–1042% DV depending on reference), and zinc bisglycinate chelate provides 15 mg elemental zinc (100% DV) with high amino acid-chelate bioavailability. Succinic acid (50–150 mg) and, in select formulations, 100 mg desiccated stomach substance/intrinsic factor complete the micronutrient complex; the tablets contain no significant macronutrients, fiber, or caloric value.
How It Works
Mechanism of Action
In the PIC matrix, ferric iron (Fe³⁺) is non-covalently complexed with low-molecular-weight polysaccharide chains, protecting it from precipitation at physiological gastric pH and releasing iron gradually in the absorptive mucosa; ascorbic acid co-formulated within the tablet reduces Fe³⁺ to Fe²⁺ at the brush border, enabling uptake via the divalent metal transporter 1 (DMT1/SLC11A2) on duodenal enterocyte apical membranes. Ferrous asparto glycinate enters enterocytes as an intact amino acid chelate through peptide and amino acid transporter pathways (PepT1, CAT1), bypassing the DMT1-dependent pathway and reducing competition with other divalent minerals such as zinc and calcium. Once absorbed, free iron is bound to transferrin in portal blood and delivered to erythroid precursors in bone marrow, where it is incorporated into protoporphyrin IX by ferrochelatase to form heme, the prosthetic group of hemoglobin that enables cooperative oxygen binding. Succinic acid may further support iron bioavailability by maintaining intracellular reducing conditions and serving as a substrate in the citric acid cycle, sustaining the ATP-dependent processes necessary for ferroportin (FPN1/SLC40A1)-mediated basolateral iron export from enterocytes into the bloodstream.
Clinical Evidence
No large-scale, brand-specific RCTs for Niferex with published hemoglobin outcomes, serum ferritin changes, or anemia resolution rates were identified in the available literature. The formulation is indicated for iron deficiency anemia treatment and prevention based on regulatory classification as a prescription iron supplement, supported by indirect evidence from studies on polysaccharide-iron complexes and ferrous asparto glycinate in broadly similar patient populations. Comparative tolerability data from class-level studies suggest reduced GI side effect burden relative to ferrous sulfate at equivalent elemental doses, which may improve patient adherence in outpatient settings. Confidence in clinical efficacy specifically attributable to the Niferex combination formulation (including succinic acid, intrinsic factor, and the dual-iron matrix) remains low due to the absence of Niferex-specific placebo-controlled or active-comparator trials with sufficient statistical power.
Safety & Interactions
At the labeled once-daily dose, Niferex is generally well-tolerated; potential adverse effects include nausea, constipation, dark stools, and epigastric discomfort, though the incidence of these events is reported to be lower than with ferrous sulfate based on class-level tolerability data for chelated and polysaccharide-bound iron forms. Critical drug interactions include: tetracycline and fluoroquinolone antibiotics (iron chelates reduce absorption of both the antibiotic and iron when co-administered), levothyroxine (iron significantly reduces thyroid hormone bioavailability; separate by at least 4 hours), levodopa and methyldopa (iron forms insoluble chelates reducing drug efficacy), and antacids containing calcium, magnesium, or aluminum (reduce iron absorption). Niferex is contraindicated in individuals with hemochromatosis, hemosiderosis, polycythemia, or other conditions involving iron overload, and the FD&C Yellow #6 colorant in some tablet versions poses an allergy risk in aspirin-sensitive individuals; it is not FDA-approved as a drug product and is regulated as a prescription dietary supplement in the United States. Pregnancy and lactation safety should be individually assessed by a healthcare provider, as the 150 mg elemental iron dose substantially exceeds standard prenatal iron recommendations (27–45 mg/day) and high-dose iron during pregnancy carries theoretical risks of oxidative stress without established safety data specific to this formulation.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Polysaccharide-Iron Complex (PIC)Ferrous Asparto GlycinateSumalate ironNiferex-150Non-ionic iron complex
Frequently Asked Questions
What is Iron Niferex and how is it different from regular iron supplements?
Iron Niferex is a branded iron supplement that delivers elemental iron via two advanced matrices: polysaccharide-iron complex (PIC), where ferric iron is bound to low-molecular-weight polysaccharide chains, and ferrous asparto glycinate (Sumalate®), an amino acid chelate of ferrous iron. Unlike standard ferrous sulfate, these forms protect iron from gastric precipitation, reduce free ionic iron in the GI lumen, and utilize alternative enterocyte transport pathways, resulting in significantly less GI irritation such as nausea, constipation, and epigastric pain while maintaining effective iron delivery for hemoglobin synthesis.
What is the recommended dosage of Iron Niferex for iron deficiency anemia?
The standard adult dose of Niferex is one coated tablet taken once daily, providing 150 mg of elemental iron alongside supportive nutrients including vitamin C (60–175 mg), folate (1 mg as Quatrefolic® and folic acid), vitamin B12 (25 mcg), and zinc (15 mg). This dose is substantially higher than general maintenance iron recommendations, and therapy duration for iron deficiency anemia typically spans 3–6 months until both hemoglobin normalization and ferritin repletion are achieved under the guidance of a healthcare provider.
Does Iron Niferex cause constipation or stomach upset?
Iron Niferex is formulated specifically to reduce the GI side effects associated with conventional iron salts; the polysaccharide-iron complex and amino acid chelate structures sequester reactive ionic iron, minimizing direct oxidative damage to the intestinal mucosa that causes nausea, constipation, and dark stools. While GI side effects are possible with any iron supplement at 150 mg elemental iron doses, class-level tolerability comparisons suggest chelated and polysaccharide-bound iron forms produce fewer and less severe GI complaints than ferrous sulfate at equivalent elemental doses; taking the tablet with a small amount of food may further reduce discomfort.
Are there any medications that interact with Iron Niferex?
Iron Niferex interacts with several important drug classes: tetracycline and fluoroquinolone antibiotics form insoluble chelates with iron that reduce both antibiotic and iron absorption — separate dosing by at least 2 hours is required; levothyroxine bioavailability is significantly reduced when co-administered with iron, necessitating a minimum 4-hour separation; and levodopa, methyldopa, and bisphosphonate drugs are similarly affected by iron chelation in the GI tract. Antacids, dairy products, coffee, and tea also inhibit iron absorption and should be avoided within 2 hours of taking Niferex.
Is Iron Niferex safe during pregnancy?
The safety of Niferex specifically during pregnancy has not been established in dedicated clinical trials, and caution is warranted because its 150 mg elemental iron dose considerably exceeds standard prenatal iron recommendations of 27–45 mg/day established by organizations such as the American College of Obstetricians and Gynecologists. High-dose iron supplementation during pregnancy is associated with theoretical oxidative stress risks and potential interference with zinc absorption; therefore, use of Niferex during pregnancy or lactation should only occur under direct supervision of a licensed healthcare provider who has assessed individual iron status, confirmed iron deficiency diagnosis, and determined that the clinical benefit outweighs potential risk.
How does Iron Niferex absorption compare to ferrous sulfate and other iron forms?
Iron Niferex combines polysaccharide-iron complex and ferrous asparto glycinate to enhance bioavailability while reducing GI irritation compared to ferrous sulfate, which is more likely to cause constipation and nausea. The polysaccharide coating in Niferex protects iron in the stomach and allows gradual release in the intestines, optimizing absorption without overwhelming the intestinal mucosa. Clinical studies show that Niferex formulations deliver comparable or superior elemental iron absorption to ferrous salts while maintaining superior tolerability, making it suitable for patients with sensitive digestive systems.
How long does it typically take for Iron Niferex to improve anemia symptoms?
Noticeable improvements in fatigue and weakness may occur within 2–4 weeks as hemoglobin levels begin to rise, though complete iron repletion typically requires 2–3 months of consistent supplementation. The 150 mg daily elemental iron dose is designed for rapid ferritin replenishment, with serum ferritin levels often stabilizing within 8–12 weeks in most patients with iron deficiency anemia. Individual response varies based on the severity of deficiency, ongoing blood loss, and gastrointestinal absorption capacity.
Is Iron Niferex suitable for patients with inflammatory bowel disease or malabsorption conditions?
Iron Niferex may be better tolerated in inflammatory bowel disease (IBD) and malabsorption conditions compared to ferrous salts due to its gentler polysaccharide-iron complex formulation, which causes less mucosal irritation. However, patients with severe IBD or celiac disease should consult their healthcare provider, as intestinal inflammation can still impair iron absorption regardless of formulation. In these cases, iron dosing adjustments, timing relative to meals, and monitoring of hemoglobin and ferritin levels are essential to ensure therapeutic efficacy.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w iron-niferex-polysaccharide-iron-complex-ferrous-asparto-glycinate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
